Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. Treatment recommendations are provided by an expert panel. Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission. Although the 2005 pediatric ALL evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome positive (Ph+) ALL in C...
The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in child...
Although improved donor sources and supportive care have decreased transplantation-related mortality...
Context: Survival after allogeneic hematopoietic stem-cell transplantation (HSCT) for children with ...
AbstractEvidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy...
AbstractClinical research examining the role of hematopoietic stem cell transplantation (SCT) in the...
Clinical research published since the first evidence-based review on the role of hematopoietic stem ...
Purpose of Review: The remarkable improvement in the prognosis of children with acute lymphoblastic ...
The indications for hematopoietic stem cell transplantation (HSCT) in pediatric leukemias continuall...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not allogeneic SCT ...
Identification of pediatric patients with acute myeloid leukemia (AML) candidates to receive allogen...
AbstractSurvival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when...
AbstractEvidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy...
The concurrent administration of tyrosine kinase inhibitors (TKIs) with standard chemotherapy togeth...
Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) still represents a major challenge. We ...
BackgroundPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) remained until rec...
The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in child...
Although improved donor sources and supportive care have decreased transplantation-related mortality...
Context: Survival after allogeneic hematopoietic stem-cell transplantation (HSCT) for children with ...
AbstractEvidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy...
AbstractClinical research examining the role of hematopoietic stem cell transplantation (SCT) in the...
Clinical research published since the first evidence-based review on the role of hematopoietic stem ...
Purpose of Review: The remarkable improvement in the prognosis of children with acute lymphoblastic ...
The indications for hematopoietic stem cell transplantation (HSCT) in pediatric leukemias continuall...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not allogeneic SCT ...
Identification of pediatric patients with acute myeloid leukemia (AML) candidates to receive allogen...
AbstractSurvival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when...
AbstractEvidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy...
The concurrent administration of tyrosine kinase inhibitors (TKIs) with standard chemotherapy togeth...
Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) still represents a major challenge. We ...
BackgroundPhiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) remained until rec...
The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in child...
Although improved donor sources and supportive care have decreased transplantation-related mortality...
Context: Survival after allogeneic hematopoietic stem-cell transplantation (HSCT) for children with ...